Conmed Analyst Ratings
Conmed Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 23.96% | Needham | $140 → $119 | Maintains | Buy |
| 07/27/2023 | 51.04% | JP Morgan | $125 → $145 | Maintains | Overweight |
| 07/27/2023 | 45.83% | Needham | $139 → $140 | Maintains | Buy |
| 07/27/2023 | 46.88% | Keybanc | $131 → $141 | Maintains | Overweight |
| 07/24/2023 | 44.79% | Needham | → $139 | Reiterates | Buy → Buy |
| 06/05/2023 | 44.79% | Needham | $135 → $139 | Maintains | Buy |
| 05/22/2023 | 45.83% | CL King | → $140 | Initiates Coverage On | → Buy |
| 04/27/2023 | 35.42% | Stifel | $118 → $130 | Maintains | Buy |
| 04/27/2023 | 33.33% | Piper Sandler | $118 → $128 | Maintains | Overweight |
| 04/27/2023 | 23.96% | Wells Fargo | $96 → $119 | Maintains | Equal-Weight |
| 04/27/2023 | 40.63% | Needham | $122 → $135 | Maintains | Buy |
| 04/27/2023 | 36.46% | Keybanc | $124 → $131 | Maintains | Overweight |
| 03/27/2023 | 29.17% | Keybanc | → $124 | Upgrades | Sector Weight → Overweight |
| 02/03/2023 | 22.92% | Piper Sandler | $108 → $118 | Maintains | Overweight |
| 02/03/2023 | 27.08% | Needham | $106 → $122 | Maintains | Buy |
| 11/15/2022 | 10.42% | Needham | $90 → $106 | Maintains | Buy |
| 10/14/2022 | -6.25% | Needham | $123 → $90 | Maintains | Buy |
| 10/12/2022 | -11.46% | Jefferies | → $85 | Initiates Coverage On | → Hold |
| 08/02/2022 | 28.13% | Needham | $127 → $123 | Maintains | Buy |
| 07/28/2022 | 22.92% | Piper Sandler | $160 → $118 | Maintains | Overweight |
| 07/28/2022 | 32.29% | Needham | $155 → $127 | Maintains | Buy |
| 06/23/2022 | 14.58% | Stifel | $160 → $110 | Maintains | Buy |
| 05/05/2022 | 61.46% | Needham | $150 → $155 | Maintains | Buy |
| 01/21/2022 | 56.25% | Needham | $158 → $150 | Maintains | Buy |
| 10/28/2021 | 64.58% | Needham | $150 → $158 | Maintains | Buy |
| 10/06/2021 | 56.25% | Needham | → $150 | Upgrades | Hold → Buy |
| 07/15/2021 | 66.67% | UBS | → $160 | Initiates Coverage On | → Buy |
| 05/25/2021 | 82.29% | Barclays | → $175 | Initiates Coverage On | → Overweight |
| 04/29/2021 | 66.67% | Piper Sandler | $145 → $160 | Maintains | Overweight |
| 07/30/2020 | -1.04% | Piper Sandler | $90 → $95 | Maintains | Overweight |
| 07/30/2020 | 4.17% | Stifel | $82 → $100 | Maintains | Buy |
| 07/30/2020 | -4.17% | SVB Leerink | $82 → $92 | Maintains | Market Perform |
| 04/30/2020 | -14.58% | Stifel | $65 → $82 | Maintains | Buy |
| 04/23/2020 | -20.83% | JP Morgan | $136 → $76 | Maintains | Overweight |
| 11/26/2019 | — | Needham | Downgrades | Buy → Hold | |
| 11/12/2019 | 41.67% | JP Morgan | → $136 | Initiates Coverage On | → Overweight |
| 10/31/2019 | 22.92% | Stifel | $99 → $118 | Maintains | Buy |
| 08/22/2019 | 14.58% | Piper Sandler | $88 → $110 | Upgrades | Neutral → Overweight |
| 08/01/2019 | 3.13% | Stifel | $97 → $99 | Maintains | Buy |
| 04/18/2019 | -1.04% | Stifel | → $95 | Initiates Coverage On | → Buy |
| 04/15/2019 | -4.17% | Barclays | $85 → $92 | Maintains | Overweight |
| 02/19/2019 | -11.46% | Barclays | → $85 | Reinstates | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月26日 | 23.96% | 李約瑟 | $140→$119 | 維護 | 買 |
| 07/27/2023 | 51.04% | 摩根大通 | $125→$145 | 維護 | 超重 |
| 07/27/2023 | 45.83% | 李約瑟 | $139→$140 | 維護 | 買 |
| 07/27/2023 | 46.88% | KeyBanc | $131→$141 | 維護 | 超重 |
| 07/24/2023 | 44.79% | 李約瑟 | →$139 | 重申 | 購買→購買 |
| 06/05/2023 | 44.79% | 李約瑟 | $135→$139 | 維護 | 買 |
| 2023年05月22日 | 45.83% | CL國王 | →$140 | 開始承保 | →購買 |
| 04/27/2023 | 35.42% | Stifel | $118→$130 | 維護 | 買 |
| 04/27/2023 | 33.33% | 派珀·桑德勒 | $118→$128 | 維護 | 超重 |
| 04/27/2023 | 23.96% | 富國銀行 | $96→$119 | 維護 | 等重 |
| 04/27/2023 | 40.63% | 李約瑟 | $122→$135 | 維護 | 買 |
| 04/27/2023 | 36.46% | KeyBanc | $124→$131 | 維護 | 超重 |
| 03/27/2023 | 29.17% | KeyBanc | →$124 | 升級 | 行業權重→超配 |
| 02/03/2023 | 22.92% | 派珀·桑德勒 | $108→$118 | 維護 | 超重 |
| 02/03/2023 | 27.08% | 李約瑟 | $106→$122 | 維護 | 買 |
| 2022年11月15日 | 10.42% | 李約瑟 | $90→$106 | 維護 | 買 |
| 10/14/2022 | -6.25% | 李約瑟 | $123→$90 | 維護 | 買 |
| 10/12/2022 | -11.46% | 傑富瑞 | →$85 | 開始承保 | →保留 |
| 08/02/2022 | 28.13% | 李約瑟 | $127→$123 | 維護 | 買 |
| 07/28/2022 | 22.92% | 派珀·桑德勒 | $160→$118 | 維護 | 超重 |
| 07/28/2022 | 32.29% | 李約瑟 | $155→$127 | 維護 | 買 |
| 2022/06/23 | 14.58% | Stifel | $160→$110 | 維護 | 買 |
| 05/05/2022 | 61.46% | 李約瑟 | $150→$155 | 維護 | 買 |
| 2022年01月21日 | 56.25% | 李約瑟 | $158→$150 | 維護 | 買 |
| 10/28/2021 | 64.58% | 李約瑟 | $150→$158 | 維護 | 買 |
| 10/06/2021 | 56.25% | 李約瑟 | →$150 | 升級 | 持有→購買 |
| 07/15/2021 | 66.67% | 瑞銀集團 | →$160 | 開始承保 | →購買 |
| 2021/05/25 | 82.29% | 巴克萊 | →$175 | 開始承保 | →超重 |
| 04/29/2021 | 66.67% | 派珀·桑德勒 | $145→$160 | 維護 | 超重 |
| 07/30/2020 | -1.04% | 派珀·桑德勒 | $90→$95 | 維護 | 超重 |
| 07/30/2020 | 4.17% | Stifel | $82→$100 | 維護 | 買 |
| 07/30/2020 | -4.17% | SVB Leerink | $82→$92 | 維護 | 市場表現 |
| 04/30/2020 | -14.58% | Stifel | $65→$82 | 維護 | 買 |
| 04/23/2020 | -20.83% | 摩根大通 | $136→$76 | 維護 | 超重 |
| 2019年11月26日 | - | 李約瑟 | 評級下調 | 購買→Hold | |
| 2019年11月12日 | 41.67% | 摩根大通 | →$136 | 開始承保 | →超重 |
| 2019年10月31日 | 22.92% | Stifel | $99→$118 | 維護 | 買 |
| 2019年08月22日 | 14.58% | 派珀·桑德勒 | $88→$110 | 升級 | 中性→超重 |
| 2019年08月01日 | 3.13% | Stifel | $97→$99 | 維護 | 買 |
| 2019/04/18 | -1.04% | Stifel | →$95 | 開始承保 | →購買 |
| 2019年04月15日 | -4.17% | 巴克萊 | $85→$92 | 維護 | 超重 |
| 2019年02月19日 | -11.46% | 巴克萊 | →$85 | 恢復 | →超重 |
What is the target price for Conmed (CNMD)?
康美德(CNMD)的目標價是多少？
The latest price target for Conmed (NYSE: CNMD) was reported by Needham on October 26, 2023. The analyst firm set a price target for $119.00 expecting CNMD to rise to within 12 months (a possible 23.96% upside). 16 analyst firms have reported ratings in the last year.
Needham於2023年10月26日報告了Conmed(紐約證券交易所代碼：CNMD)的最新目標價。這家分析公司將目標價定為119.00美元，預計CNMD將在12個月內上漲至23.96%。過去一年，有16家分析公司公佈了評級。
What is the most recent analyst rating for Conmed (CNMD)?
康美德(CNMD)的最新分析師評級是多少？
The latest analyst rating for Conmed (NYSE: CNMD) was provided by Needham, and Conmed maintained their buy rating.
Conmed(紐約證券交易所代碼：CNMD)的最新分析師評級由Needham提供，Conmed維持其買入評級。
When is the next analyst rating going to be posted or updated for Conmed (CNMD)?
Conmed(CNMD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Conmed的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Conmed的上一次評級是在2023年10月26日提交的，所以你應該預計下一次評級將在2024年10月26日左右提供。
Is the Analyst Rating Conmed (CNMD) correct?
分析師評級Conmed(CNMD)正確嗎？
While ratings are subjective and will change, the latest Conmed (CNMD) rating was a maintained with a price target of $140.00 to $119.00. The current price Conmed (CNMD) is trading at is $96.00, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但康美德(Conmed)最新的評級維持不變，目標價在140.00美元至119.00美元之間。康美德(CNMD)目前的交易價格為96.00美元，超出了分析師的預測區間。